W18
Gene TherapyNanomedicine
Active

Sixfold Bioscience

Nanoparticles to deliver cell and gene therapies.

Sixfold is focused on preclinical research and development of its patented nanoparticle drug delivery systems for Cell & Gene therapeutics such as siRNAs for gene silencing and mRNAs for gene expression. To aid this development, Sixfold has expanded its capabilities in computational biology and artificial intelligence (AI)/machine learning. While product approvals and a regulatory focus have made 2017-2019 a breakthrough time for Cell & Gene therapies, the focus now moves to finding safe and effective delivery system to help unlock their true clinical and commercial potential. Sixfold is dedicated to solving the drug delivery challenge, helping to bring true precision medicine to patients. To help realize its vision, Sixfold is involved in multiple collaborative projects in the UK: e.g. with the National Physical Laboratory Ltd, the LGC Ltd, Imperial College London, UCL; in the EU: e.g. Technical University of Eidhoven; and beyond: the National Institutes of Health (NIH, USA). Sixfold has been featured by: Business Weekly, Financial Times, Forbes, Oxford University’s Merton College, the Maserati 100 & The Sunday Times, TechCrunch, Cambridge University’s Judge Business School, BioBeat 50 Movers and Shakers in BioBusiness 2018.

Sixfold Bioscience
Founded2018
Team Size10
LocationLondon, United Kingdom

George Foot

Anna Perdrix Rosell

Anna Perdrix Rosell
Sixfold Bioscience